Cargando…

HER-2-Positive Ampullary Adenocarcinoma: A Case Report

Background: Ampullary adenocarcinomas are a rare subset of periampullary tumors with an overall poor prognosis. Treatment decisions are generally extrapolated from pancreatic chemotherapy protocols and consist mainly of traditional chemotherapy drugs. There are no known targets for therapeutic inter...

Descripción completa

Detalles Bibliográficos
Autores principales: O'Hayer, Kevin, Farber, John, Yeo, Charles J., Sama, Ashwin R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc., publishers 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6319676/
https://www.ncbi.nlm.nih.gov/pubmed/30631802
http://dx.doi.org/10.1089/crpc.2015.29004.koh
_version_ 1783385103382085632
author O'Hayer, Kevin
Farber, John
Yeo, Charles J.
Sama, Ashwin R.
author_facet O'Hayer, Kevin
Farber, John
Yeo, Charles J.
Sama, Ashwin R.
author_sort O'Hayer, Kevin
collection PubMed
description Background: Ampullary adenocarcinomas are a rare subset of periampullary tumors with an overall poor prognosis. Treatment decisions are generally extrapolated from pancreatic chemotherapy protocols and consist mainly of traditional chemotherapy drugs. There are no known targets for therapeutic intervention in ampullary adenocarcinoma at this time. Next generation sequencing and other novel molecular profiling of tumors, including circulating tumor DNA (ctDNA), have recently made it possible to better understand tumor biology and elucidate driver mutations which are amenable to targeted therapy. This case describes the use of novel DNA sequencing technology to provide a targeted treatment option, HER-2 inhibition, in a patient with HER-2 overexpressing ampullary adenocarcinoma. This is the first time this has been described in the literature. Case presentation: The patient is a 63-year-old Caucasian man who initially presented with symptoms of obstructive jaundice and was found to have a periampullary tumor. He underwent resection of his tumor and pathology confirmed a stage IIB ampullary adenocarcinoma. He unfortunately developed a recurrence in the liver and lung two years later. Next generation sequencing of his tumor at the time of resection as well as ctDNA analysis demonstrated a HER-2 overexpressing tumor. Following first line therapy with FOLFOX he had progression and was treated with trastuzumab and pertuzumab with stabilization of his disease prior to his ultimate demise from multifocal pneumonia. Conclusion: The use of next generation sequencing as well as ctDNA technology generated a novel therapeutic intervention in our patient. As these techniques become more widespread, it is likely more targeted therapies will be used in these difficult to treat diseases.
format Online
Article
Text
id pubmed-6319676
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Mary Ann Liebert, Inc., publishers
record_format MEDLINE/PubMed
spelling pubmed-63196762019-01-10 HER-2-Positive Ampullary Adenocarcinoma: A Case Report O'Hayer, Kevin Farber, John Yeo, Charles J. Sama, Ashwin R. Case Rep Pancreat Cancer Case Report Background: Ampullary adenocarcinomas are a rare subset of periampullary tumors with an overall poor prognosis. Treatment decisions are generally extrapolated from pancreatic chemotherapy protocols and consist mainly of traditional chemotherapy drugs. There are no known targets for therapeutic intervention in ampullary adenocarcinoma at this time. Next generation sequencing and other novel molecular profiling of tumors, including circulating tumor DNA (ctDNA), have recently made it possible to better understand tumor biology and elucidate driver mutations which are amenable to targeted therapy. This case describes the use of novel DNA sequencing technology to provide a targeted treatment option, HER-2 inhibition, in a patient with HER-2 overexpressing ampullary adenocarcinoma. This is the first time this has been described in the literature. Case presentation: The patient is a 63-year-old Caucasian man who initially presented with symptoms of obstructive jaundice and was found to have a periampullary tumor. He underwent resection of his tumor and pathology confirmed a stage IIB ampullary adenocarcinoma. He unfortunately developed a recurrence in the liver and lung two years later. Next generation sequencing of his tumor at the time of resection as well as ctDNA analysis demonstrated a HER-2 overexpressing tumor. Following first line therapy with FOLFOX he had progression and was treated with trastuzumab and pertuzumab with stabilization of his disease prior to his ultimate demise from multifocal pneumonia. Conclusion: The use of next generation sequencing as well as ctDNA technology generated a novel therapeutic intervention in our patient. As these techniques become more widespread, it is likely more targeted therapies will be used in these difficult to treat diseases. Mary Ann Liebert, Inc., publishers 2015-11-01 /pmc/articles/PMC6319676/ /pubmed/30631802 http://dx.doi.org/10.1089/crpc.2015.29004.koh Text en © Kevin O'Hayer et al. 2015; Published by Mary Ann Liebert, Inc. This Open Access article is distributed under the terms of the Creative Commons License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.
spellingShingle Case Report
O'Hayer, Kevin
Farber, John
Yeo, Charles J.
Sama, Ashwin R.
HER-2-Positive Ampullary Adenocarcinoma: A Case Report
title HER-2-Positive Ampullary Adenocarcinoma: A Case Report
title_full HER-2-Positive Ampullary Adenocarcinoma: A Case Report
title_fullStr HER-2-Positive Ampullary Adenocarcinoma: A Case Report
title_full_unstemmed HER-2-Positive Ampullary Adenocarcinoma: A Case Report
title_short HER-2-Positive Ampullary Adenocarcinoma: A Case Report
title_sort her-2-positive ampullary adenocarcinoma: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6319676/
https://www.ncbi.nlm.nih.gov/pubmed/30631802
http://dx.doi.org/10.1089/crpc.2015.29004.koh
work_keys_str_mv AT ohayerkevin her2positiveampullaryadenocarcinomaacasereport
AT farberjohn her2positiveampullaryadenocarcinomaacasereport
AT yeocharlesj her2positiveampullaryadenocarcinomaacasereport
AT samaashwinr her2positiveampullaryadenocarcinomaacasereport